Release Date: March 15, 2013
National Cancer Institute (NCI)
This Notice is to inform potential applicants that the National Cancer Institute (NCI) Cancer Therapy Evaluation Program will hold a pre-application teleconference meeting for RFA CA-13-006, entitled NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN) (UM1).
The teleconference meeting is intended to explain the goals and objectives of this initiative and to answer questions from prospective applicants.
The meeting is open to all prospective applicants. Participation in the meeting, although encouraged, is optional and not required for application submission.
The meeting is optional and open to the public. However, investigators planning to participate must pre-register by e-mail to [email protected] no later than by April 2, 2013. In the e-mail, please provide your name, affiliation, and contact information.
When: Wednesday, April 3, 2013, 1:00 PM 3:00 PM Eastern Standard Time (U.S. and Canada EST).
Place: Virtual Meeting phone number available upon registration.
Questions may be submitted by e-mail in advance and during the teleconference to: [email protected]. While an effort will be made to include all questions in the teleconference discussion, it is possible that not all will be addressed during the meeting due to time constraints.
An archive of the meeting will be posted on the CTEP website as a public resource as soon as possible after the meeting.
Please direct all inquiries to:
S. Percy Ivy, M.D.
Investigational Drug Branch
Cancer Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
Telephone: 301-496-1196
Email: [email protected]
and Human Services (HHS)
